Category - Developments

Developments

Theravance launches education campaign for nOH associated with MSA

Theravance Biopharma (NASDAQ: TBPH) has announced the launch of Power in the Periphery—a new disease education campaign to raise awareness and deepen scientific understanding of the pathophysiology underlying neurogenic...

October 16, 2025

Developments

First patient dosed in Adicet’s trial of ADI-001 in RA

Adicet Bio (NASDAQ: ACET) has announced that the first patient has been dosed in its Phase 1 clinical trial evaluating ADI-001 in treatment-refractory rheumatoid arthritis (RA). The company’s Phase 1 study is designed...

October 16, 2025

Developments

CervoMed reports new data from trial showing potential of neflamapimod for DLB

CervoMed (NASDAQ: CRVO) has announced additional data from its Phase 2b RewinD-LB trial, demonstrating neflamapimod’s potential as a treatment for dementia with Lewy bodies (DLB). According to CervoMed, FDA feedback on...

October 8, 2025

Developments

USPTO grants Aquestive two patents for Anaphylm

Aquestive Therapeutics (NASDAQ: AQST) has announced that the USPTO has issued two additional patents extending protection into 2037 for Anaphylm, a novel epinephrine prodrug sublingual film. According to Aquestive, if...

October 8, 2025

Developments

Profound sees record revenues in Q3-2025; up 84-87% YoY with higher gross margin

Profound Medical (NASDAQ: PROF; TSX: PRN) announced that it anticipates total revenues for the third quarter of 2025 to be in the approximate range of $5.2 million to $5.3 million, representing YoY revenue growth of...

October 7, 2025

Developments

PharmaJet initiates development of needle-free injection pens for home use

Closely held PharmaJet has announced that it is expanding its needle-free injection portfolio with the development of a suite of proprietary, needle-free, self-injector pens. The single-use and reusable needle-free...

October 7, 2025

Developments

FDA grants ALTO fast track designation for treatment of CIAS

Alto Neuroscience (NYSE: ANRO) announced that the FDA has granted its novel small molecule PDE4 inhibitor, ALTO-101, fast track designation for the treatment of cognitive impairment associated with schizophrenia (CIAS)...

October 6, 2025

Developments

Aspire files omnibus patent application with USPTO for drug delivery platform

Aspire Biopharma Holdings (NASDAQ: ASBP) has announced the filing of an omnibus patent application with the USPTO for its sublingual drug delivery technology. According to Aspire, the technology is designed to enhance...

October 6, 2025

Developments

First patient dosed in Perspective’s study of PSV359 in FAP-a positive solid tumors

Perspective Therapeutics (NYSE American: CATX) has announced that the first patient has been dosed in the second cohort of a Phase 1/2a dose-finding trial to determine the safety and preliminary anti-tumor activity of...

October 2, 2025

Developments

Profusa adds leading CLTI surgeon to customer base

Profusa (NASDAQ: PFSA) has announced that Yann Gouëffic, MD, PhD, professor of vascular surgery in the Vascular Center at Groupe Hospitalier Paris Saint Joseph, Paris, France will adopt the company’s Lumee oxygen...

October 1, 2025

Category - Developments

Subscribe